• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

FGFR2 激活突变破坏细胞极性,增强子宫内膜癌细胞模型中的迁移和侵袭。

FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.

机构信息

School of Biomedical Sciences, Queensland University of Technology (QUT) located at the Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia

The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia.

出版信息

J Cell Sci. 2018 Aug 10;131(15):jcs213678. doi: 10.1242/jcs.213678.

DOI:10.1242/jcs.213678
PMID:30002137
Abstract

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that control a diverse range of biological processes during development and in adult tissues. We recently reported that somatic FGFR2 mutations are associated with shorter survival in endometrial cancer. However, little is known about how these FGFR2 mutations contribute to endometrial cancer metastasis. Here, we report that expression of the activating mutations FGFR2 and FGFR2 in an endometrial cancer cell model induce Golgi fragmentation, and loss of polarity and directional migration. In mutant FGFR2-expressing cells, this was associated with an inability to polarise intracellular pools of FGFR2 towards the front of migrating cells. Such polarization defects were exacerbated in three-dimensional culture, where FGFR2 mutant cells were unable to form well-organised acini, instead undergoing exogenous ligand-independent invasion. Our findings uncover collective cell polarity and invasion as common targets of disease-associated FGFR2 mutations that lead to poor outcome in endometrial cancer patients.

摘要

成纤维细胞生长因子受体(FGFRs)是受体酪氨酸激酶家族的一员,在发育过程中和成人组织中控制着多种生物学过程。我们最近报道称,体细胞 FGFR2 突变与子宫内膜癌患者的生存率降低有关。然而,这些 FGFR2 突变如何促进子宫内膜癌转移的机制尚不清楚。在这里,我们报告称,在子宫内膜癌细胞模型中表达激活突变的 FGFR2 和 FGFR2 会诱导高尔基体碎片化,并导致极性和定向迁移丧失。在表达突变 FGFR2 的细胞中,这与无法将细胞内 FGFR2 池极化到迁移细胞的前缘有关。在三维培养中,这种极化缺陷更加严重,突变型 FGFR2 细胞无法形成组织良好的腺泡,而是经历外源性配体非依赖性侵袭。我们的研究结果揭示了细胞集体极性和侵袭是与疾病相关的 FGFR2 突变的共同靶点,这些突变导致子宫内膜癌患者预后不良。

相似文献

1
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.FGFR2 激活突变破坏细胞极性,增强子宫内膜癌细胞模型中的迁移和侵袭。
J Cell Sci. 2018 Aug 10;131(15):jcs213678. doi: 10.1242/jcs.213678.
2
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.成纤维细胞生长因子受体抑制剂多韦替尼(TKI258)和 NVP-BGJ398 在人子宫内膜癌细胞中的活性。
Mol Cancer Ther. 2013 May;12(5):632-42. doi: 10.1158/1535-7163.MCT-12-0999. Epub 2013 Feb 26.
3
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.FGFR2 中的 N550K/H 突变导致对 PD173074、多韦替尼和普纳替尼等 ATP 竞争性抑制剂产生不同程度的耐药性。
Neoplasia. 2013 Aug;15(8):975-88. doi: 10.1593/neo.121106.
4
Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.AZD4547对FGFR2失调的子宫内膜癌细胞的抗肿瘤作用及机制
Mol Cancer Ther. 2015 Oct;14(10):2292-302. doi: 10.1158/1535-7163.MCT-15-0032. Epub 2015 Aug 20.
5
Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.波纳替尼对携带激活型FGFR2突变的子宫内膜癌细胞的抗肿瘤作用及分子机制
Cancer Biol Ther. 2016;17(1):65-78. doi: 10.1080/15384047.2015.1108492.
6
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.成纤维细胞生长因子受体抑制与紫杉醇和多柔比星在子宫内膜癌细胞中协同作用。
Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806.
7
Drug-sensitive FGFR2 mutations in endometrial carcinoma.子宫内膜癌中的药物敏感性成纤维细胞生长因子受体2(FGFR2)突变
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.
8
Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.通过自分泌激活 FGF 受体和 HES1 表达促进低分化子宫内膜癌细胞的增殖。
Hum Cell. 2019 Jul;32(3):367-378. doi: 10.1007/s13577-019-00249-1. Epub 2019 Apr 8.
9
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.尽管PTEN缺失,但抑制子宫内膜癌细胞中活化的成纤维细胞生长因子受体2会诱导细胞死亡。
Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770.
10
Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.Bcl-2 抑制剂增强 FGFR 抑制剂诱导的 FGFR2 突变型子宫内膜癌中线粒体依赖性细胞死亡。
Mol Oncol. 2019 Apr;13(4):738-756. doi: 10.1002/1878-0261.12422. Epub 2019 Jan 18.

引用本文的文献

1
FGFR2 residence in primary cilia is necessary for epithelial cell signaling.成纤维细胞生长因子受体2(FGFR2)定位于初级纤毛对于上皮细胞信号传导是必要的。
J Cell Biol. 2025 Jul 7;224(7). doi: 10.1083/jcb.202311030. Epub 2025 Apr 21.
2
Targeted therapies in hepatocellular carcinoma: past, present, and future.肝细胞癌的靶向治疗:过去、现在与未来
Front Oncol. 2024 Aug 29;14:1432423. doi: 10.3389/fonc.2024.1432423. eCollection 2024.
3
Compression-dependent microtubule reinforcement enables cells to navigate confined environments.压缩依赖型微管强化使细胞能够在受限环境中导航。
Nat Cell Biol. 2024 Sep;26(9):1520-1534. doi: 10.1038/s41556-024-01476-x. Epub 2024 Aug 19.
4
Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.利用人工智能算法检测子宫内膜癌中的驱动基因突变和基因组特征。
PLoS One. 2024 Feb 26;19(2):e0299114. doi: 10.1371/journal.pone.0299114. eCollection 2024.
5
FGFR families: biological functions and therapeutic interventions in tumors.成纤维细胞生长因子受体家族:肿瘤中的生物学功能与治疗干预
MedComm (2020). 2023 Sep 23;4(5):e367. doi: 10.1002/mco2.367. eCollection 2023 Oct.
6
The Alterations and Roles of Glycosaminoglycans in Human Diseases.糖胺聚糖在人类疾病中的改变与作用
Polymers (Basel). 2022 Nov 18;14(22):5014. doi: 10.3390/polym14225014.
7
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology.系统评价神经母细胞瘤病理生理学中的受体酪氨酸激酶超家族。
Cancer Metastasis Rev. 2022 Mar;41(1):33-52. doi: 10.1007/s10555-021-10001-7. Epub 2021 Oct 30.
8
Terminal 10q26.12 deletion is associated with neonatal asymmetric crying facies syndrome: a case report and literature review.10号染色体长臂26.12区末端缺失与新生儿不对称哭泣面容综合征相关:一例报告及文献综述
Mol Cytogenet. 2021 Jul 13;14(1):36. doi: 10.1186/s13039-021-00554-1.
9
FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention.肝细胞癌中的FGF/FGFR信号传导:从致癌作用到近期的治疗干预
Cancers (Basel). 2021 Mar 17;13(6):1360. doi: 10.3390/cancers13061360.
10
Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.在癌症治疗中抑制 FGF-FGFR 和 VEGF-VEGFR 信号通路。
Cell Prolif. 2021 Apr;54(4):e13009. doi: 10.1111/cpr.13009. Epub 2021 Mar 2.